# ENDRA Life Sciences Inc.: Form 10-Q for the period ended Jun 30, 2022

- Company: [ENDRA Life Sciences Inc.](/companies/ndra.md) (CIK 1681682)
- Form: 10-Q
- Filed: 2022-08-15
- Accepted by EDGAR: Aug 15, 2022, 17:47 ET
- Period: 2022-06-30
- Accession: 0001654954-22-011398
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1681682/000165495422011398/ndra_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1681682/000165495422011398/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2022-04-01 to 2022-06-30 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2022-01-01 to 2022-06-30 | $3.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | −$3.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | −$6.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-04-01 to 2022-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2022-01-01 to 2022-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | −$3.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | −$6.4m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | −$6.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-01-01 to 2022-06-30 | $149.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-06-30 | $11.3m | us-gaap:Cash |
| Current assets | at 2022-06-30 | $14.5m | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $15.3m | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $1.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-06-30 | $2.0m | us-gaap:Liabilities |
| Long-term debt | at 2022-06-30 | $472.7k | us-gaap:LongTermDebt |
| Shareholders' equity | at 2022-06-30 | $13.3m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1681682/000165495422011398/ndra_10q.htm

Filed Aug 15, 2022.
Source: SEC EDGAR, the filing index for accession 0001654954-22-011398. Last ingested by Listed: Nov 10, 2026, 17:03 ET. No prices; not investment advice.
